MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)*
Organization & Developments: BioCryst
Parents
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)*
Children
*BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases
*Publicly traded company that has made strides with its flu treatment drug Peramivir
*Uses structure-based drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicin
2011: BioCryst invests $5M into pipeline that includes gout, hepatitis C drugs
2019: BioCryst Pharmaceuticals Is In A Very Tough Position After BCX7353 Phase 3 'Success'_seekingalpha.com
2019: BioCryst Pharmaceuticals: Waiting For A Cash Infusion_seekingalpha.com
2019: BioCryst: An Oral Drug Competing Against An Approved Injection_seekingalpha.com
2020: Antivirals Rather Than Vaccines For COVID-19
2020: BioCryst Pharmaceuticals: BCX9930's Competitive Profile In PNH Patients
2020: BioCryst Pharmaceuticals: Important Catalysts Could Drive Additional Upside In 2H 2020
2020: BioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang Removed
2020: BioCryst: What Past Data Says About Galidesivir In SARS-CoV-2
2021: BioCryst: Solid Delivery And Follow Through
2022: BioCryst Pharmaceuticals (BCRX) Investor Presentation -Slideshow_ seekingalpha.com
2022: BioCryst Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo_seekingalpha.com
2022: BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo_ seekingalpha.com
2023: Analyzing BioCryst's Position Amid Pharvaris' HAE Breakthrough_ seekingalpha.com
2023: BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run (NASDAQ:BCRX)
2024: BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
2024: BioCryst stock rides Orladeyo wave amid pipeline shifts
2024: BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
2024: BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
2024: U.S. Government Awards BioCryst $69 Million RAPIVAB®
Jumps
*Key People: BioCryst
Finance & Acquisitions: BioCryst